首页> 美国卫生研究院文献>Nature Communications >Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity
【2h】

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

机译:OP-1074的特定立体化学破坏雌激素受体α螺旋12并赋予纯的抗雌激素活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates. Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay. We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model. Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.
机译:雌激素受体(ER)产生的复杂的组织特异性和细胞特异性信号通常会导致对乳腺癌的内分泌治疗产生抗药性。完全缺乏组织特异性激动剂活性的纯ER拮抗剂有望预防和治疗内分泌抵抗,但是缺乏结构信息阻碍了新型候选药物的开发。在这里,我们合成了一小组带有可变侧链的苯并吡喃,以在子宫营养测定中鉴定纯的抗雌激素。我们确定OP-1074为纯抗雌激素药和选择性ER降解剂(PA-SERD),在对他莫昔芬耐药的异种移植模型中有效缩小肿瘤。生化和晶体结构分析表明,结构活性关系暗示了OP-1074吡咯烷侧链(尤其是螺旋12)上的立体有择甲基的重要性。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号